Chopra Daveen 4
4 · Edwards Lifesciences Corp · Filed May 8, 2026
Research Summary
AI-generated summary of this filing
Edwards Lifesciences CVP Daveen Chopra Receives Stock Awards
What Happened
Daveen Chopra, CVP, TMTT & Surgical at Edwards Lifesciences (EW), received equity awards on May 7, 2026 and had shares withheld to cover tax liabilities. The filing shows:
- Time-based restricted stock units (RSUs): 9,675 shares granted (acquired at $0.00).
- Stock options: 49,100 granted (derivative award, $0.00 acquisition reported).
- Performance RSU target award: 9,675 target shares granted (derivative; actual vesting 0–200% based on performance).
To cover tax withholding/related payments, Chopra had 674 shares disposed on 2026-05-07 at $83.20 each ($56,077) and 1,141 shares disposed on 2026-05-08 at $82.76 each ($94,429), totaling 1,815 shares and $150,506.
Key Details
- Transaction dates & prices:
- Grants dated May 7, 2026: 9,675 RSUs; 49,100 options; 9,675 performance-target RSUs (reported at $0.00 acquisition price).
- Tax-withholding disposals: May 7, 2026 — 674 shares @ $83.20 ($56,077); May 8, 2026 — 1,141 shares @ $82.76 ($94,429).
- Shares withheld/sold for taxes: 1,815 shares; total proceeds used for tax/payment = $150,506.
- Shares owned after transaction: Not specified in this Form 4 (the filing notes it reflects changes only).
- Vesting/vesting terms (footnotes):
- Time-based RSUs and options vest in four equal annual installments beginning one year after grant.
- Performance RSUs vest May 7, 2029 subject to 0–200% payout based on a three-year performance period.
- Filing timeliness: Form 4 filed May 8, 2026 (covers activity on May 7–8); no late filing flag noted.
Context
- These were compensation awards (RSUs, options, performance RSUs), not open-market purchases — awards reflect company compensation, not necessarily a direct bullish signal.
- The disposals were tax-withholding/cashless-type actions (code F), common when RSUs vest or awards are granted; they do not necessarily reflect a voluntary sale for investment reasons.
- Options and time-based RSUs require future vesting before Chopra can sell underlying shares; performance RSU payout depends on achieving targets through 2029.
Insider Transaction Report
Form 4
Chopra Daveen
CVP, TMTT & Surgical
Transactions
- Award
Common Stock
[F1]2026-05-07+9,675→ 41,594 total - Tax Payment
Common Stock
2026-05-07$83.20/sh−674$56,077→ 40,920 total - Tax Payment
Common Stock
2026-05-08$82.76/sh−1,141$94,429→ 39,779 total - Award
Employee Stock Option (Right to Acquire)
[F2]2026-05-07+49,100→ 49,100 totalExercise: $82.76From: 2027-05-07Exp: 2033-05-06→ Common Stock (49,100 underlying) - Award
Performance Rights
[F3]2026-05-07+9,675→ 9,675 totalFrom: 2029-05-07→ Common Stock (9,675 underlying)
Footnotes (3)
- [F1]These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- [F2]These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- [F3]Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.
Signature
Linda J. Park, Attorney-in-Fact|2026-05-08